安替可胶囊联合GP方案治疗晚期原发性肝癌的临床研究  

Clinical study on Antike Capsules combined with gisitabine and cisplatin in treatment of advanced primary liver cancer

作　　者：王全晖 袁守信 张元浩 郭明辉 WANG Quan-hui;YUAN Shou-xin;ZHANG Yuan-hao;GUO Ming-hui(Department of General Hepatobiliary Surgery, No.153 Central Hospital of PLA, Zhengzhou 450042, China)

机构地区：[1]中国人民解放军第一五三中心医院普外肝胆科,河南郑州450042

出　　处：《现代药物与临床》2019年第3期709-713,共5页Drugs & Clinic

摘　　要：目的探讨安替可胶囊联合吉西他滨和顺铂治疗晚期原发性肝癌的临床疗效。方法选取2014年4月—2015年4月在中国人民解放军第一五三中心医院治疗的晚期原发性肝癌患者86例,根据用药的差别分为对照组(43例)和治疗组(43例)。对照组静脉滴注注射用盐酸吉西他滨,1 000 mg/m^2,1次/周,连续治疗3周,休息1周,同时静脉滴注顺铂注射液,80 mg/m^2,1次/d,连续治疗3 d,间隔3周再治疗。治疗组在对照组基础上饭后口服安替可胶囊,2粒/次,3次/d。两组均患者均治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者甲胎蛋白(AFP)、癌胚抗原(CEA)、糖抗原(CA242)、α-L-岩藻糖苷酶(AFU)、血管内皮生长因子(VEGF)、骨桥蛋白(OPN)、可溶性白细胞介素-2受体(sIL-2R)、缺氧诱导因子-2α(HIF-2α)水平。结果治疗后,对照组患者ORR和CBR分别为41.86%和72.09%,均分别显著低于治疗组的69.77%和86.05%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清AFP、CEA、CA242、AFU、VEGF、OPN、sIL-2R、HIF-2α水平均显著降低,同组比较差异具有统计学意义(P<0.05),且治疗后治疗组患者上述肿瘤标志物水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论安替可胶囊联合吉西他滨和顺铂治疗晚期原发性肝癌可显著降低机体肿瘤标志物水平,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Antike Capsules combined with gisitabine and cisplatin in treatment of advanced primary liver cancer. Methods Patients(86 cases) with advanced primary liver cancer in the No.153 Central Hospital of PLA from April 2014 to April 2015 were divided into control(43 cases) and treatment(43 cases) groups based on different treatments.Patients in the control group were iv administered with Gemcitabine Hydrochloride Injection, 1 000 mg/m^2, once a week, and they were treated for 3 weeks and rested for 1 week. At the same time, they were iv administered with Cisplatin Injection for 3 d, 80 mg/m^2, once daily, then re-treated at intervals of 3 weeks. Patients in the treatment group were po administered with Antike Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the AFP, CEA, CA242, AFU, VEGF, OPN, sIL-2 R and HIF-2α levels in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 41.86% and 72.09%,which were significantly lower than 69.77% and 86.05% in the treatment group, respectively, and there were differences between two groups(P < 0.05). After treatment, the AFP, CEA, CA242, AFU, VEGF, OPN, sIL-2 R, and HIF-2α levels in two groups were significantly decreased(P < 0.05), and the difference was statistically significant in the same group(P < 0.05), and these indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Antike Capsules combined with gisitabine and cisplatin in treatment of advanced primary liver cancer can significantly reduce the level of tumor markers, which has a certain clinical application value.

关 键 词：安替可胶囊 注射用盐酸吉西他滨 顺铂注射液 晚期原发性肝癌 甲胎蛋白 癌胚抗原 骨桥蛋白 可溶性白细胞介素-2受体 

分 类 号：R979.1[医药卫生—药品]